Bristol Myers Squibb (BMY) Consolidated Net Income (2009 - 2026)

Bristol Myers Squibb (BMY) reported Consolidated Net Income of $2.7 billion for Q1 2026, up 8.81% year-over-year from $2.5 billion in Q1 2025, and up 146.69% quarter-over-quarter from $1.1 billion in Q4 2025.

Bristol Myers Squibb (BMY) Consolidated Net Income (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (BMY) has 18 years of Consolidated Net Income data on file, last reported at $2.7 billion in Q1 2026.

  • Consolidated Net Income for Q1 2026 came in at $2.7 billion, up 8.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (up 33.77% YoY), and the FY2025 annual result was $7.1 billion, up 178.99% from the prior year.
  • Consolidated Net Income rose to $2.7 billion in Q1 2026 per BMY's latest filing, from $1.1 billion in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
  • A 5-year average of $893.4 million and a median of $1.7 billion in 2024 frame the typical range for Consolidated Net Income.
  • The sharpest annual moves came in 2024 and 2025: Consolidated Net Income sank 625.28% in 2024, then soared 1328.95% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at $2.0 billion in 2022, then dropped by 12.99% to $1.8 billion in 2023, then sank by 95.69% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
  • Business Quant data shows BMY's Consolidated Net Income at $2.7 billion in Q1 2026, $1.1 billion in Q4 2025, and $2.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -13.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.68 Bn
Dec 31, 2025 1.09 Bn
Sep 30, 2025 2.20 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 2.46 Bn
Dec 31, 2024 76.00 Mn
Sep 30, 2024 1.22 Bn
Jun 30, 2024 1.68 Bn
Mar 31, 2024 -11.91 Bn
Dec 31, 2023 1.76 Bn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 2.08 Bn
Mar 31, 2023 2.27 Bn
Dec 31, 2022 2.03 Bn
Sep 30, 2022 1.61 Bn
Jun 30, 2022 1.43 Bn
Mar 31, 2022 1.28 Bn
Dec 31, 2021 2.37 Bn
Sep 30, 2021 1.55 Bn
Jun 30, 2021 1.06 Bn